Pharsight

1. Isturisa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8835646	RECORDATI RARE	Organic compounds	Aug, 2026 (2 years from now)
US8314097	RECORDATI RARE	Organic compounds	Mar, 2029 (4 years from now)
US9434754	RECORDATI RARE	Use of an adrenal hormone-modifying agent	Jan, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862	RECORDATI RARE	Use of an adrenal hormone-modifying agent	Jan, 2031 (6 years from now)
US10143680	RECORDATI RARE	Pharmaceutical dosage forms	Jul, 2035 (11 years from now)
US10709691	RECORDATI RARE	Pharmaceutical dosage forms	Oct, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 06, 2025
Orphan Drug Exclusivity(ODE-286)	Mar 06, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 06 March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 10MG BASE	TABLET;ORAL	Discontinued
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 1MG BASE	TABLET;ORAL	Prescription

ISTURISA family patents

2. Neoprofen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6344479	RECORDATI RARE	Method of preventing retinopathy of prematurity in a neonate	Mar, 2021 (3 years ago)
US8415337	RECORDATI RARE	Ibuprofen compositions and methods of making same	Mar, 2032 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6342530	RECORDATI RARE	Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt	Nov, 2020 (3 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Apr 13, 2013

Drugs and Companies using IBUPROFEN LYSINE ingredient

Market Authorisation Date: 13 April, 2006

Treatment: Treatment of patent ductus arteriosus; Closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500g, who are no more than 32 weeks gestational age w...

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg/mL, 2 mL vials	01 Oct, 2010	1	30 Mar, 2016	20 Mar, 2021	Extinguished Deferred

Strength	Dosage	Availability
EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	INJECTABLE;INTRAVENOUS	Prescription

NEOPROFEN family patents

3. Signifor patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6225284	RECORDATI RARE	Somatostatin peptides	Jun, 2016 (7 years ago)
US8299209	RECORDATI RARE	Pharmaceutical composition comprising cyclic somatostatin analogues	Dec, 2025 (1 year, 8 months from now)
US7473761	RECORDATI RARE	Somatostatin analogues	Dec, 2026 (2 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-34)	Dec 14, 2019
Orphan Drug Exclusivity(ODE)	Dec 14, 2019
New Chemical Entity Exclusivity(NCE)	Dec 14, 2017

Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient

NCE-1 date: 14 December, 2016

Market Authorisation Date: 14 December, 2012

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription
EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription
EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

SIGNIFOR family patents

4. Signifor Lar Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6225284	RECORDATI RARE	Somatostatin peptides	Jun, 2016 (7 years ago)
US7473761	RECORDATI RARE	Somatostatin analogues	Dec, 2026 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637	RECORDATI RARE	Somatostatin analogues	Aug, 2023 (8 months ago)
US7759308	RECORDATI RARE	Microparticles comprising somatostatin analogues	Oct, 2026 (2 years from now)
US9351923	RECORDATI RARE	Extended-release composition comprising a somatostatin derivative in microparticles	May, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-268)	Jun 29, 2025
New Indication(I-785)	Jun 29, 2021
Orphan Drug Exclusivity(ODE)	Dec 15, 2021
New Chemical Entity Exclusivity(NCE)	Dec 14, 2017
New Product(NP)	Dec 15, 2017
Orphan Drug Exclusivity(ODE-81)	Dec 15, 2021

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

NCE-1 date: 14 December, 2016

Market Authorisation Date: 29 June, 2018

Treatment: Method of treating acromegaly; Method of treating disorders with an etiology comprising or associated with excess gh-secretion

Dosage: FOR SUSPENSION;INTRAMUSCULAR